Dr. Lisa Palko joins Mindsigns Health™ as Advisor, Neuroscience

📣 Mindsigns Health™, a global neuropsychiatry platform, is pleased to announce the appointment of Dr. Lisa Palko as Advisor, Neuroscience.

Dr. Palko specializes in the development and implementation of digital health and prescription digital therapeutics with extensive experience in mental health, digital health technologies, and population behavior change internationally.

Dr. Palko is also the Executive Director of the Society for Digital Mental Health (SDMH). She has held senior leadership positions in Neuroscience spanning multinational pharmaceutical companies such as Otsuka Pharmaceuticals and Sunovion Pharmaceuticals (now Sumitomo Pharma America) to young companies such as AKILI Inc (first FDA approved digital therapeutic for ADHD) to name a few.

She is also a lecturer in neuropsychiatry at the University of Pittsburgh, and has had papers published as lead and co-author in topics ranging from neuropsychiatry, therapeutics, public health and policy as well as countless presentations on these topics.

“We are honored that Dr. Lisa Palko has decided to join us as an advisor during an important period for Mindsigns Health™ as the company expands clinical collaborations and advances commercialization of its product platform. Lisa has unique skills and background which combine deep clinical, policy and regulatory experience, with hands-on leadership positions building and scaling digital healthcare products and strategy. As Mindsigns Health™ enters its commercialization phase, Lisa’s entrepreneurial perspective, industry knowledge and relationships, and understanding of how innovative technologies are adopted by providers and reimbursed by payers will be invaluable. I look forward to her guidance and Mindsigns Health™ is delighted to welcome Lisa to the team.”

Michel Birnbaum
CEO
Mindsigns Health™

“I’m excited to join Mindsigns Health™ and contribute to a team that is thinking creatively about the future of neuroscience and mental health. GenMind™ and NeuroBrowser™ are particularly promising examples of how innovative technology can open new possibilities for understanding and advancing care for people with mental health and neurological conditions. I look forward to bringing my experience across neuroscience, digital health, medical affairs, and commercialization to help advance these products and build partnerships that can expand their impact.”

Lisa Palko, PharmD